It has been four years since then and the access still remains limited. It was called a novel strategy to deal with HIV, however, there not has been public rollout and government too has not distributed it. This means awareness remain low and the cost is too high for everyone to afford it. PrEP is available for Rs 2,200 to Rs. 3,000 a month in private markets and at subsidized rates in just a few handful of non-profits that too in select cities.

HIV was first identified in 1986 in India, since then the country has made gradual progress in controlling the disease. As per the Sankalak, Status of National AIDS and STD Response Report 2024, released by NACO, HIV prevalence among adults, which is considered between 15 to 49 years was 0.20 per cent. This represented a 44 per cent decline since 2010.

However, the prevalence and incidence remain high in vulnerable populations. While the incidence in general population was 0.05 per 1,000 uninfected persons in 2023, men who have sex with men (MSM) see an incidence of 1.55, Hijra/Transgender persons (HTG) have 2.76, and female sex workers (FSW) are at 3.33. This means that nearly a million of FSWs, 350,000 MSM and 96,000 HTGs have the disease. A report from India Spend notes that it is not an actual headcount, but an estimation, which represents that the real number could be more than that.

How Does PrEP Work?

HIV spreads in the human body by targeting and infecting T cells or the critical white blood cells of our immune system. PrEP blocks HIV from replicating inside T cells after exposure. It stops the infection from taking hold. PrEP has also come in form of oral pill which could reduce the chances of contracting HIV through sexual contact or injection drug use.

Studies have documented a sharp fall in HIV infections in communities where Pre-Exposure Prophylaxis (PrEP) is widely used. In Australia, a study involving more than 62,000 people found that government-subsidized oral PrEP helped reduce new HIV cases by 78% among men who took the medication for at least 60% of days between 2018 and 2023. PrEP works best when taken daily, lowering the risk of HIV transmission through sex by over 99% and by more than 74% through infected needles. It can be stopped when a person is no longer engaged in high-risk activities such as having multiple sexual partners or injecting drugs.

Last year, the United States Food and Drug Administration (FDA) approved twice-yearly injectable PrEP, lenacapavir. The World Health Organization recommended for a fast rollout. Maker Gilead Sciences signed agreements with generic manufacturers, including Dr Reddy's Laboratories, to make the jab available in 120 low- and middle-income countries at lower cost.

Amid this, Zimbabwe become the first African country to roll out the breakthrough injection, while Japan approved the pill version made by Gilead Sciences - Truvada.

Read more news like this on www.healthandme.com